Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.

<h4>Background</h4>In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM.<h4>Patients and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bo Yang, Rui-li Yu, Xiao-hua Chi, Xue-chun Lu
Format:	article
Language:	EN
Published:	Public Library of Science (PLoS) 2013
Subjects:	Medicine R Science Q
Online Access:	https://doaj.org/article/df36b7601dfa412d9924d73b25364d55
Tags:	Add Tag No Tags, Be the first to tag this record!

id	oai:doaj.org-article:df36b7601dfa412d9924d73b25364d55
record_format	dspace
spelling	oai:doaj.org-article:df36b7601dfa412d9924d73b25364d552021-11-18T07:45:45ZLenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.1932-620310.1371/journal.pone.0064354https://doaj.org/article/df36b7601dfa412d9924d73b25364d552013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23691202/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM.<h4>Patients and methods</h4>Databases were searched using the terms "lenalidomide or revlimid AND multiple myeloma."RCTs evaluating initial or maintenance therapeutic outcomes were included. Main outcome measures were response rates, progression-free survival (PFS), overall survival, and adverse events.<h4>Results</h4>Seven trials were included (N = 192-614 participants). Lenalidomide doses and treatment regimens differed between trials. Complete response (CR) and very good partial response (VGPR) risk ratios (RR) favored lenalidomide over placebo (CR = 2.54, 95% confidence interval [CI] = 1.29-5.02; VGPR = 2.82, 95% CI = 1.30-6.09). The PFS hazard ratio favored lenalidomide over placebo (0.37, 95% CI = 0.33-0.41). For adverse events, neutropenia, deep vein thrombosis (DVT), infection, and hematologic cancer RR favored placebo over lenalidomide (neutropenia: 4.74, 95% CI = 2.96-7.57; DVT: 2.52; 95% CI: 1.60-3.98; infection: 1.98; 95% CI: 1.50-2.62; hematologic cancer: 3.20; 95% CI: 1.28-7.98).<h4>Conclusions</h4>Lenalidomide is an effective treatment for MM; however, treatment-related adverse events must be considered and appropriate adjustments and/or prophylactic treatment should be initiated where possible.Bo YangRui-li YuXiao-hua ChiXue-chun LuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e64354 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bo Yang Rui-li Yu Xiao-hua Chi Xue-chun Lu Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
description	<h4>Background</h4>In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM.<h4>Patients and methods</h4>Databases were searched using the terms "lenalidomide or revlimid AND multiple myeloma."RCTs evaluating initial or maintenance therapeutic outcomes were included. Main outcome measures were response rates, progression-free survival (PFS), overall survival, and adverse events.<h4>Results</h4>Seven trials were included (N = 192-614 participants). Lenalidomide doses and treatment regimens differed between trials. Complete response (CR) and very good partial response (VGPR) risk ratios (RR) favored lenalidomide over placebo (CR = 2.54, 95% confidence interval [CI] = 1.29-5.02; VGPR = 2.82, 95% CI = 1.30-6.09). The PFS hazard ratio favored lenalidomide over placebo (0.37, 95% CI = 0.33-0.41). For adverse events, neutropenia, deep vein thrombosis (DVT), infection, and hematologic cancer RR favored placebo over lenalidomide (neutropenia: 4.74, 95% CI = 2.96-7.57; DVT: 2.52; 95% CI: 1.60-3.98; infection: 1.98; 95% CI: 1.50-2.62; hematologic cancer: 3.20; 95% CI: 1.28-7.98).<h4>Conclusions</h4>Lenalidomide is an effective treatment for MM; however, treatment-related adverse events must be considered and appropriate adjustments and/or prophylactic treatment should be initiated where possible.
format	article
author	Bo Yang Rui-li Yu Xiao-hua Chi Xue-chun Lu
author_facet	Bo Yang Rui-li Yu Xiao-hua Chi Xue-chun Lu
author_sort	Bo Yang
title	Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
title_short	Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
title_full	Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
title_fullStr	Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
title_full_unstemmed	Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
title_sort	lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/df36b7601dfa412d9924d73b25364d55
work_keys_str_mv	AT boyang lenalidomidetreatmentformultiplemyelomasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ruiliyu lenalidomidetreatmentformultiplemyelomasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaohuachi lenalidomidetreatmentformultiplemyelomasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xuechunlu lenalidomidetreatmentformultiplemyelomasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
_version_	1718423005311270912

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.

Similar Items